annual meeting program - American Society of Clinical Oncology

8:00 AM - 12:00 PM
POSTER DISCUSSION SESSION
Melanoma/Skin Cancers
Display Time: 8:00 AM - 12:00 PM
Display Location: S403
Discussion Time: 11:00 AM - 12:00 PM
Discussion Location: S406 (Vista Room)
CME credit: 1
Track(s): Melanoma/Skin Cancers
Monday, June 7, 2010
Ravi K. Amaravadi, MD—Co-Chair
University of Pennsylvania
Gregory A. Daniels, MD, PhD—Co-Chair
University of California, San Diego Moores Cancer Center
Discussion
11:00 AM Julie R. Lange, MD (Abstracts #8513–8517)
The Johns Hopkins University School of Medicine
Discussion
11:15 AM David F. McDermott, MD (Abstracts #8518–8522)
Beth Israel Deaconess Medical Center
Discussion
11:30 AM Henry B. Koon, MD (Abstracts #8523–8526)
Ireland Cancer Center/University Hospital
Discussion
11:45 AM Anna C. Pavlick, MD (Abstracts #8527–8532)
New York University Cancer Institute
Brd. 1 Evaluation of minimal residual disease (MRD) in peripheral blood (PB)
assessed prospectively by RT-PCR for melanoma-associated genes as an
independent prognostic factor for survival in stage III melanoma (Mel)
patients (pts) enrolled onto an intergroup adjuvant trial S0008. (Abstract
#8513)
J. A. Sosman, J. Moon, P. Liu, L. E. Flaherty, M. B. Atkins, K. A. Margolin,
J. M. Kirkwood, V. K. Sondak
Brd. 2 Early ultrasound criteria drive sensitivity for detection of sentinel node
metastases in melanoma patients: A prospective study in 800 patients.
(Abstract #8514)
C. A. Voit, A. C. Van Akkooi, G. Schaefer-Hesterberg, A. Schoengen, W. Sterry,
A. M. Eggermont
Brd. 3 Report card for compliance with NCCN guidelines in the surgical
management of cutaneous melanoma across the United States: Time for
remedial classes? (Abstract #8515)
N. Wasif, R. J. Gray, B. A. Pockaj
Brd. 4 Unraveling the prognostic heterogeneity in patients with advanced
melanoma between Australia (OZ) and the United States (US): Preliminary
report of the PHAMOUS study. (Abstract #8516)
M. B. Atkins, G. V. Long, C. L. Warneke, M. Carlino, E. R. DeRose, M. M. Johnson,
P. T. Brown, M. Lee, R. Kefford, J. E. Gershenwald
Brd. 5 Should unknown primary melanomas be excluded from adjuvant therapy
trials? Insights from SWOG S0008. (Abstract #8517)
V. K. Sondak, R. Tuthill, J. Moon, J. A. Thompson, C. D. Lao, B. G. Redman,
L. E. Flaherty
Brd. 6 Activity of sunitinib in advanced malignant melanoma and its correlation with
potential predictive biomarkers. (Abstract #8518)
L. Decoster, B. Neyns, I. Vande Broek, E. Anckaert, D. De Clerck, J. De Mey,
F. Majois, J. Baurain, H. Denys, J. De Greve
299
MONDAY